A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Society of Interventional Radiology Position Statement: Endovascular Management Deemed An Acceptable Treatment Option for Certain Iliofemoral DVT Patients

The Society of Interventional Radiology (SIR) published a position statement deeming endovascular thrombus removal “an acceptable treatment option in selected patients with acute iliofemoral deep vein thrombosis.” The position statement was published online today on the Journal of Vascular and Interventional Radiology (JVIR) website.

SIR convened a multidisciplinary writing group that conducted a comprehensive literature review. The group used evidence from 84 studies—including randomized trials, systematic reviews and meta-analyses, prospective single-arm studies, and retrospective studies—to develop 17 recommendations to guide the use of endovascular venous intervention for the care of patients with acute iliofemoral DVT.

Among the key recommendations were for physicians to quickly identify DVT and provide prompt and adequate anticoagulation, symptom control and functional recovery at the time of diagnosis. For those with anatomically extensive and clinically severe DVT and low bleeding risk, a form of catheter directed thrombolysis (CDT) is reasonable to use in carefully selected patients after evaluating their co-morbidities and personal preferences.

“Endovascular management has been used to treat select patients with acute iliofemoral DVT for more than 25 years, but newer and better-designed studies have shown us that such interventions are most effective and safest when applied to younger patients with severe DVT symptoms,” said Suresh Vedantham, MD, FSIR, the lead author and an interventional radiologist with the Washington University in St. Louis.

“Most DVT patients will benefit from anticoagulation alone, and can be spared anything more invasive, but for those who are suffering from severe symptoms or are at the highest risk of developing lifestyle-limiting post-thrombotic syndrome, catheter-directed therapies are appropriate and effective in reducing symptom severity early and late,” said Vedantham. Vedantham was the primary investigator on the ATTRACT Trial, the findings of which were published in 2017 and informed the new recommendations. Vedantham lauded the efforts of the international thrombosis research community in conducting several pivotal randomized trials to enable well-informed guidelines, and the strong support of the SIR Foundation in the development and conduct of ATTRACT.

Based on the findings of the ATTRACT trial, the position statement authors recommend against the use of CDT for most patients with DVT that is limited to the tibial, popliteal, and femoral veins, for patients with clinical factors that confer a moderate or high risk for bleeding, and for patients with only mild lower extremity symptoms.

“Patient selection is the most important factor for success in the application of interventional treatments,” said, Kush R. Desai, MD, FSIR, chair of SIR’s Venous Disease Clinical Specialty Council, a co-author of the statement, and an interventional radiologist with Northwestern Medicine in Chicago. “Our recommendations follow the evidence so those who may benefit from endovascular treatment options are quickly identified to receive care and ensure positive outcomes.”

“Timing of intervention for acute deep vein thrombosis is important to optimize outcomes,” said Ronald S. Winokur, MD, FSIR, vice chair of SIR’s Venous Disease Clinical Specialty Council, co-author of the statement, and an interventional radiology with Weill Cornell Medicine in New York. “Clear guidance on patient selection including an understanding of extent of disease and accounting for flow dynamics helps patients receive the best treatment at the right time.”

As further research proceeds, SIR believes that adherence to the recommendations in the position statement allow for the use of endovascular therapy in a manner that optimizes benefit and minimizes harm.

“SIR is dedicated to the evidence-based practice of interventional radiology and ensuring our position statements and guidelines reflect the findings of the latest science so patients receive the best possible care,” said SIR President Parag J. Patel, MD, FSIR, an interventional radiologist with the Medical College of Wisconsin. “Thank you to the authors for their time and energy to ensure that DVT patients have access to the care appropriate for their case and medical history.”

Full statement here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy